Amylyx Pharmaceuticals Beat Consensus Estimates
Thursday, May 8, 2025 at 7:00 AM ET
Amylyx Pharmaceuticals (AMLX) reported a loss of $0.42 per share on revenue of $0.00 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.45 per share on revenue of $0.65 million. The company beat consensus estimates by 6.67% while revenue fell 100.00% compared to the same quarter a year ago.
Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.42
Earnings Whisper®
-
Consensus Estimate
$-0.45
Earnings Surprise
Earnings Growth
Reported Revenue
-
Revenue Estimate
$650.00 Thou
Revenue Surprise
Revenue Growth